Literature DB >> 27109707

Non-covalent carriage of anticancer agents by humanized antibody trastuzumab.

Arpita Yadav1, Sweta Sharma2, Veejendra Kumar Yadav3.   

Abstract

This article explores the internalization and non-covalent carriage of small molecule anticancer agents like vinca alkaloids by humanized monoclonal antibody trastuzumab. Such carriage is marked by significant reduction in side effects and increased therapeutic value of these anticancer agents. This study is coherent with few clinical observations of enhanced efficiency of these anticancer agents when co-administered with therapeutic antibodies. This study will also serve as the foundation for screening a database of anticancer agents for possible compounds that may be co-delivered alongwith the antibody. Based on this study vincristine conformation inside antibody and its charge environment may be used as descriptors for screening purposes.

Entities:  

Keywords:  Binding energy; MMGBSA; Molecular docking; Molecular dynamics; Monoclonal antibody; Non-covalent carriage; Simulation; Solvation free energy; Trastuzumab; Vinca alkaloid

Mesh：

Substances：

Year:  2016        PMID： 27109707     DOI： 10.1007/s00894-016-2986-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN： 0948-5023            Impact factor:   1.810


  19 in total

1.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.

Authors:  Thomas A Halgren; Robert B Murphy; Richard A Friesner; Hege S Beard; Leah L Frye; W Thomas Pollard; Jay L Banks
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

2.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

3.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

4.  Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.

Authors:  Joshua M Donaldson; Cindy Zer; Kendra N Avery; Krzysztof P Bzymek; David A Horne; John C Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

Review 5.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

Review 6.  Areas, volumes, packing and protein structure.

Authors:  F M Richards
Journal:  Annu Rev Biophys Bioeng       Date:  1977

7.  Preparation and characterization of a biodegradable drug targeting system for anticancer drug delivery: microsphere-antibody conjugate.

Authors:  Asli Muvaffak; Ismet Gurhan; Ufuk Gunduz; Nesrin Hasirci
Journal:  J Drug Target       Date:  2005-04       Impact factor: 5.121

8.  Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.

Authors:  Tao Liu; Yong Zhang; Yan Liu; Ying Wang; Haiqun Jia; Mingchao Kang; Xiaozhou Luo; Dawna Caballero; Jose Gonzalez; Lance Sherwood; Vanessa Nunez; Danling Wang; Ashley Woods; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

9.  Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A.

Authors:  W D Graf; P F Chance; M W Lensch; L J Eng; H P Lipe; T D Bird
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860

10.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors:  J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.